Abstract
林东昕,唐永明,陆士新,Fred F.Kadlubar.谷胱甘肽转硫酶M1和T1基因型与食管癌危险性:病例-对照研究[J].Chinese journal of Epidemiology,1998,19(4):195-199
谷胱甘肽转硫酶M1和T1基因型与食管癌危险性:病例-对照研究
Glutathione S - Transferase M1, T1 Genotypes and the Risk of Esophageal Cancer: A Case - Control Study
Received:January 06, 1998  Revised:February 17, 1998
DOI:
KeyWord: 食管癌  谷胱甘肽转硫酶  基因多型性  分子流行病学
English Key Word: Esophageal cancer  Glutathione S-transferase  Genetic polymorphisms  Molecular epidemiology
FundProject:“九五”国家医学科技攻关项目(基金编号96-906-01-06)
Author NameAffiliation
Lin Dongxin Cancer Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021 
Tang Yongming Division of Molecular Epidemiology National Center for Toxicological Research, Jefferson, Arkansas 72079, USA 
Lu Shixin Cancer Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021 
Fred F.Kadlubar Division of Molecular Epidemiology National Center for Toxicological Research, Jefferson, Arkansas 72079, USA 
Hits: 3779
Download times: 1224
Abstract:
      为探讨参与致癌物代谢的谷胱甘肽转硫酶(GST)MI和T1基因多型性与食管癌危险性的关系, 以病例-对照分子流行病学方法, 分析食管癌高发区河南林县的食管癌、食管上皮重度增生病例和性别、年龄配对的正常对照者(各45例)的GSTM1和GSTT1基因型分布的差异。基因组DNA来自研究对象的食管外科手术标本或细胞学检查获得的食管上皮细胞, 以多重聚合酶链反应方法进行基因分型。结果:食管癌、食管上皮重度增生病例和正常对照组GSTM1基因缺失率分别为44.4%、44.4%和46.7%;GSTT1基因缺失率分别为40.0%、37.8%和51.1%, 差别均无显著性。然而, 正常对照者中既是GSTMl阳性又是GSTT1阳性的基因型比例(22.2%)显著低于食管癌病例(40.0%)和食管上皮重度增生病例(37.8%), 比值比(95%可信限)分别为4.20(1.23~14.36)和2.64(0.84~8.30)。结果提示, GSTM1或GSTT1基因多型性单独似乎与食管癌危险性无关, 但两者的阳性基因型联合可能是食管癌的危险性因素。
English Abstract:
      To examine the association between genetic polymorphisms of glutathione S-transferase (GST) MI and T1 and susceptihility to esophageal cancer, a muhiplex polymerase chain reaction method was used to detect the presence or absence of the GSTM1 and GSTT1 genes in genomic DNA isolated from surgically removed esophageal tissues or scraped esiphageal cells from cases with cancer (n=45), cases with severe hyperplasia (n=45), and sex/age matched normal controls (n=45 ) from a high-risk area, Linxian. China. Results showed that the frequency of the GSTM1 - null genotype in cancer cases (44.4%) or hyperplasia cases (44.4%) was not significantly different from that in controls (46.7%). Similarly, no statistically significant differences were observed in the frequency of GSTT1-null genotype in cancer cases (40.0%) or hyperplasia cases (37.8%) when compared with the controlled population (51.1%). However, the frequency of combined GSTMI-nonnull and GSTT1-nonnull genotypes in cases with cancer (40.0%) and cases with hyperplasia (37.8%) showed a significant increase compared to that in controls (22.2%). Persons with both GSTM1 and GSTT1 positive genotypes had 4-fold risk in developing esophageal cancer (odds ratio, OR = 4.20; 95% confidence interval, (71=1.23-14.36) and 2.6 - fold risk for hyperplasia (OR = 2.64; 95% CI =0.84-8.30), respectively. These results suggest that combined GSTM1-nonnull and GSTT1-nonnull genotypes may act as risk factor in the development of esophageal cancer in Linxian population.
View Fulltext   Html FullText     View/Add Comment  Download reader
Close